Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$191.17 - $325.63 $56,395 - $96,060
-295 Reduced 6.59%
4,184 $1.36 Million
Q4 2023

Jan 31, 2024

BUY
$160.99 - $215.69 $58,600 - $78,511
364 Added 8.85%
4,479 $853,000
Q3 2023

Nov 13, 2023

SELL
$194.33 - $283.97 $6.82 Million - $9.97 Million
-35,100 Reduced 89.51%
4,115 $819,000
Q2 2023

Aug 14, 2023

BUY
$223.05 - $302.68 $7.48 Million - $10.2 Million
33,555 Added 592.84%
39,215 $11.2 Million
Q1 2023

May 08, 2023

SELL
$175.41 - $217.92 $2.04 Million - $2.53 Million
-11,626 Reduced 67.26%
5,660 $1.23 Million
Q4 2022

Feb 13, 2023

SELL
$204.38 - $296.82 $12.2 Million - $17.7 Million
-59,745 Reduced 77.56%
17,286 $3.55 Million
Q3 2022

Nov 14, 2022

BUY
$195.21 - $310.53 $13.8 Million - $21.9 Million
70,655 Added 1108.14%
77,031 $21.4 Million
Q2 2022

Aug 15, 2022

BUY
$115.91 - $214.48 $292,093 - $540,489
2,520 Added 65.35%
6,376 $1.22 Million
Q1 2022

May 13, 2022

SELL
$127.96 - $207.36 $18.4 Million - $29.8 Million
-143,526 Reduced 97.38%
3,856 $800,000
Q4 2021

Feb 14, 2022

SELL
$165.13 - $241.83 $9.93 Million - $14.5 Million
-60,162 Reduced 28.99%
147,382 $26.3 Million
Q3 2021

Nov 15, 2021

BUY
$163.99 - $235.57 $2.2 Million - $3.16 Million
13,434 Added 6.92%
207,544 $42.7 Million
Q2 2021

Aug 16, 2021

BUY
$131.45 - $201.49 $18.3 Million - $28.1 Million
139,488 Added 255.37%
194,110 $36.8 Million
Q1 2021

May 13, 2021

SELL
$92.73 - $142.05 $18.7 Million - $28.6 Million
-201,205 Reduced 78.65%
54,622 $7.12 Million
Q4 2020

Feb 12, 2021

BUY
$67.44 - $103.72 $4.13 Million - $6.34 Million
61,171 Added 31.43%
255,827 $26.5 Million
Q3 2020

Nov 12, 2020

BUY
$42.79 - $75.8 $8.33 Million - $14.8 Million
194,656 New
194,656 $14.8 Million

Others Institutions Holding SWAV

About Shockwave Medical, Inc.


  • Ticker SWAV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 35,927,100
  • Description
  • ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease ...
More about SWAV
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.